Critical appraisal of the guidelines for the management of ankylosing spondylitis: Disease-modifying antirheumatic drugs

Enrique R. Soriano, Daniel O. Clegg, Jeffrey R. Lisse

Research output: Contribution to journalArticle

3 Scopus citations


Surprisingly, little data are available for the use of disease-modifying antirheumatic drugs in ankylosing spondylitis. Sulfasalazine has been the best studied. Efficacy data for individual agents (including pamidronate) and combinations of agents are detailed in this review. Intriguingly, these agents continue to be used with some frequency, even in the absence of efficacy data. To answer these questions, additional systematic studies of these agents in ankylosing spondylitis are needed and will likely need to be done by interested collaborative groups such as SPARTAN.

Original languageEnglish (US)
Pages (from-to)357-359
Number of pages3
JournalAmerican Journal of the Medical Sciences
Issue number5
StatePublished - May 1 2012



  • Ankylosing spondylitis
  • Disease-modifying
  • Spondyloarthridities
  • Treatment

ASJC Scopus subject areas

  • Medicine(all)

Cite this